Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis

Ross Leighton,1 Jane Fitzpatrick,2,3 Helen Smith,4 Daniela Crandall,4 Carl R Flannery,4 Thierry Conrozier5 1Department of Surgery, Dalhousie University, Halifax, NS, Canada; 2Sports Medicine Professionals Pty Ltd, Richmond, VIC, Australia; 3University of Western Australia, Perth, WA, Australia; 4Bio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leighton R, Fitzpatrick J, Smith H, Crandall D, Flannery CR, Conrozier T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Osteoarthritis Viscosupplementation Intra-articular Hyaluronic acid NASHA Durolane Residence time Symptomatic relief Clinical outcomes Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/082772b22e314cbbb4a0649eef15d4c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:082772b22e314cbbb4a0649eef15d4c8
record_format	dspace
spelling	oai:doaj.org-article:082772b22e314cbbb4a0649eef15d4c82021-12-02T04:10:34ZSystematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis1179-156Xhttps://doaj.org/article/082772b22e314cbbb4a0649eef15d4c82018-05-01T00:00:00Zhttps://www.dovepress.com/systematic-clinical-evidence-review-of-nasha-durolane-hyaluronic-acid--peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XRoss Leighton,1 Jane Fitzpatrick,2,3 Helen Smith,4 Daniela Crandall,4 Carl R Flannery,4 Thierry Conrozier5 1Department of Surgery, Dalhousie University, Halifax, NS, Canada; 2Sports Medicine Professionals Pty Ltd, Richmond, VIC, Australia; 3University of Western Australia, Perth, WA, Australia; 4Bioventus LLC, Durham, NC, USA; 5Department of Rheumatology, Hospital Nord Franche-Comte, Belfort, France Background: Pain and limitations in joint mobility associated with knee osteoarthritis (OA) are clinically challenging to manage, and advanced progression of disease can often lead to total knee arthroplasty. Intra-articular injection of hyaluronic acid (HA), also referred to as viscosupplementation, is a non-surgical treatment approach for OA, the effectiveness of which may depend on the HA composition, and the length of time over which it resides in the joint. One of the available options for such therapies includes NASHA (Durolane HA), a non-animal, biofermentation-derived product, which is manufactured using a process that stabilizes the HA molecules to slow down their rate of degradation and produce a unique formulation with a terminal half-life of ~1 month. The objectives of the current review were to assess, in patients with OA of the knee, the efficacy and safety of intra-articular treatment with NASHA relative to control (saline) injections, other HA products, and other injectables (corticosteroids, platelet-rich plasma, mesenchymal stem cells).Methods: This systematic evidence review examines patient outcomes following NASHA treatment as described in published data from studies conducted in subjects with knee OA. A Preferred Reporting Items for Systematic Reviews and Meta-analyses-compliant literature search strategy yielded 11 eligible clinical studies with a variety of comparator arms. Outcomes assessed at various time points following intra-articular treatment included measures of pain, function, quality of life, and incidence of treatment-related adverse events (AEs).Results: The available evidence reported for the clinical studies assessed demonstrates sustained and effective relief of knee OA symptoms following a single injection of NASHA. In addition, an excellent biocompatibility profile is observed for NASHA as an intra-articular therapy for OA, as reflected by the low rate of AEs associated with treatment.Conclusion: Treatment with NASHA is an effective and safe single-injection procedure, which can be beneficial in the clinical management of knee OA. Keywords: osteoarthritis, viscosupplementation, intra-articular, hyaluronic acid, NASHA, Durolane, residence time, symptomatic relief, clinical outcomesLeighton RFitzpatrick JSmith HCrandall DFlannery CRConrozier TDove Medical PressarticleOsteoarthritisViscosupplementationIntra-articularHyaluronic acidNASHADurolaneResidence timeSymptomatic reliefClinical outcomesDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 10, Pp 43-54 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Osteoarthritis Viscosupplementation Intra-articular Hyaluronic acid NASHA Durolane Residence time Symptomatic relief Clinical outcomes Diseases of the musculoskeletal system RC925-935
spellingShingle	Osteoarthritis Viscosupplementation Intra-articular Hyaluronic acid NASHA Durolane Residence time Symptomatic relief Clinical outcomes Diseases of the musculoskeletal system RC925-935 Leighton R Fitzpatrick J Smith H Crandall D Flannery CR Conrozier T Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis
description	Ross Leighton,1 Jane Fitzpatrick,2,3 Helen Smith,4 Daniela Crandall,4 Carl R Flannery,4 Thierry Conrozier5 1Department of Surgery, Dalhousie University, Halifax, NS, Canada; 2Sports Medicine Professionals Pty Ltd, Richmond, VIC, Australia; 3University of Western Australia, Perth, WA, Australia; 4Bioventus LLC, Durham, NC, USA; 5Department of Rheumatology, Hospital Nord Franche-Comte, Belfort, France Background: Pain and limitations in joint mobility associated with knee osteoarthritis (OA) are clinically challenging to manage, and advanced progression of disease can often lead to total knee arthroplasty. Intra-articular injection of hyaluronic acid (HA), also referred to as viscosupplementation, is a non-surgical treatment approach for OA, the effectiveness of which may depend on the HA composition, and the length of time over which it resides in the joint. One of the available options for such therapies includes NASHA (Durolane HA), a non-animal, biofermentation-derived product, which is manufactured using a process that stabilizes the HA molecules to slow down their rate of degradation and produce a unique formulation with a terminal half-life of ~1 month. The objectives of the current review were to assess, in patients with OA of the knee, the efficacy and safety of intra-articular treatment with NASHA relative to control (saline) injections, other HA products, and other injectables (corticosteroids, platelet-rich plasma, mesenchymal stem cells).Methods: This systematic evidence review examines patient outcomes following NASHA treatment as described in published data from studies conducted in subjects with knee OA. A Preferred Reporting Items for Systematic Reviews and Meta-analyses-compliant literature search strategy yielded 11 eligible clinical studies with a variety of comparator arms. Outcomes assessed at various time points following intra-articular treatment included measures of pain, function, quality of life, and incidence of treatment-related adverse events (AEs).Results: The available evidence reported for the clinical studies assessed demonstrates sustained and effective relief of knee OA symptoms following a single injection of NASHA. In addition, an excellent biocompatibility profile is observed for NASHA as an intra-articular therapy for OA, as reflected by the low rate of AEs associated with treatment.Conclusion: Treatment with NASHA is an effective and safe single-injection procedure, which can be beneficial in the clinical management of knee OA. Keywords: osteoarthritis, viscosupplementation, intra-articular, hyaluronic acid, NASHA, Durolane, residence time, symptomatic relief, clinical outcomes
format	article
author	Leighton R Fitzpatrick J Smith H Crandall D Flannery CR Conrozier T
author_facet	Leighton R Fitzpatrick J Smith H Crandall D Flannery CR Conrozier T
author_sort	Leighton R
title	Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis
title_short	Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis
title_full	Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis
title_fullStr	Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis
title_full_unstemmed	Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis
title_sort	systematic clinical evidence review of nasha (durolane hyaluronic acid) for the treatment of knee osteoarthritis
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/082772b22e314cbbb4a0649eef15d4c8
work_keys_str_mv	AT leightonr systematicclinicalevidencereviewofnashadurolanehyaluronicacidforthetreatmentofkneeosteoarthritis AT fitzpatrickj systematicclinicalevidencereviewofnashadurolanehyaluronicacidforthetreatmentofkneeosteoarthritis AT smithh systematicclinicalevidencereviewofnashadurolanehyaluronicacidforthetreatmentofkneeosteoarthritis AT crandalld systematicclinicalevidencereviewofnashadurolanehyaluronicacidforthetreatmentofkneeosteoarthritis AT flannerycr systematicclinicalevidencereviewofnashadurolanehyaluronicacidforthetreatmentofkneeosteoarthritis AT conroziert systematicclinicalevidencereviewofnashadurolanehyaluronicacidforthetreatmentofkneeosteoarthritis
_version_	1718401349307072512

Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis

Ejemplares similares